VR Logo

Cognition Therapeutics Inc. (CGTX) download report


Healthcare | Biotechnology & Pharma Research

Cognition Therapeutics Inc. (CGTX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

IPO Date: 08-Oct-2021

CEO, Pres & Director: Ms. Lisa Ricciardi

Chief Financial Officer: Mr. James Michael O'Brien

Listing: NASDAQ: CGTX

Country: United States

Headquarters: Purchase, NY

Website: https://www.cogrx.com

Key Facts

Market cap: $50.85 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-19.18 Mln

Cash: $51.51 Mln

Total Debt: $1.40 Mln

Insider's Holding: 28.07%

Liquidity: Low

52 Week range: $1.50 - 13.80

Shares outstanding: 22,597,900

Stock Performance

Time Period Cognition Therapeutics (CGTX) S&P BSE Sensex* S&P Small-Cap 600*
YTD-57.91-7.86-18.67
1 month6.83-3.75-8.32
3 months-20.12-10.80-14.04
1 Year--1.50-16.76
3 Years--10.756.23
5 Years--11.435.72
10 Years--11.849.63
As on 05-Jul-2022 *As on 06-Jul-2022